Stefan Schreiber, ECCO 2021: Filgotinib for the Treatment of Ulcerative Colitis
TouchIMMUNOLOGY had the pleasure of talking to Professor Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, Germany) around the efficacy and safety findings from the SELECTION study and its long term extension.
The abstract ‘Safety analysis of filgotinib for Ulcerative Colitis: Results from the phase 2b/3 SELECTION study and phase 3 SELECTIONLTE long-term extension study.‘ (OP04) was presented at the 16th Congress of ECCO, July 2-3 & 8-10, 2021, Virtual.
- What did the SELECTION study and its long term extension (LTE) teach us about the efficacy of filgotinib for the treatment of ulcerative colitis (UC)? (0:14)
- What safety concerns were associated with first generation JAK inhibitors, and how does filgotinib aim to overcome these? (2:21)
- What were the findings of your safety analysis of the SELECTION and SELECTION LTE data? (3:17)
- What will be the next steps for filgotinib in UC? (6:05)
Disclosures: Stefan Schreiber reports personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, provention Bio, Protagonist, Galapagos and Falk.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ECCO 2021 (Virtual).
Share this Video
Related Videos In Digestive Disorders
UEG Digestive Health Month: Matthias Löhr, May 2023
Digestive Health Month took place over May 2023 to raise awareness of digestive diseases and cancers, which often remain overlooked in terms of policy, funding and research in Europe. We were delighted to talk with UEG’s Vice President Prof. Matthias Löhr (Karolinska Institutet, Stockholm, Sweden) around the public health and economic burden of digestive diseases, […]
Stefan Schreiber, ECCO’23: Corticosteroid-free remission with etrasimod in ulcerative colitis – analysis of the ELEVATE UC 52 study
The ELEVATE UC 52 study (NCT03945188) investigated the efficacy and safety of etrasimod in patients with moderately to severely active ulcerative colitis, a recent analysis of the study was presented at ECCO’23 looking at corticosteroid (CS)-free remission as a clinical endpoint. In this touchIMMUNOLOGY interview, we spoke with Dr. Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, […]
Stefan Schreiber, ECCO’23: Current treatment paradigm for ulcerative colitis and corticosteroid-free remission as a treatment goal
The current treatment paradigm for ulcerative colitis (UC) includes amino salicylic acid as a first line treatment followed by corticosteroids, targeted treatment and rectal topical therapy; however, with corticosteroids (CS) impacting long-term health, CS-free remission has become a long-term goal in treatment. Etrasimod is an S1P receptor modulator, recently investigated for the treatment of UC […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!